Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q1 2026 · 10-Q
Revenue$193.52M$193.52M+8.9% vs Q1 2025 Net Income$14.50M$14.50M+499.8% vs Q1 2025 EPS Diluted$0.40$0.40+471.4% vs Q1 2025 Gross Profit$117,246,000+20.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flow$57,113,000+3.1% Free Cash Flowderived$56,843,000+4.1% Margins · derivedGross margin60.6%+5.8 pt vs Q1 2025
Operating margin16.0%+3.8 pt vs Q1 2025
Net margin7.5%+6.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end